A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.

被引：0
|
作者：
Pectasides, Dimitrios G.
Karavasilis, Vasilios
Kotoula, Vassiliki
Samantas, Epaminontas
Alexopoulou, Zoi
Zagouri, Flora
Syrigos, Konstantinos N.
Koureas, Andreas
Dionysopoulos, Dimitrios
Lazaridis, Georgios
Efstratiou, Ioannis
Apessou, Dimitra
Pentheroudakis, George E.
Papaxoinis, George
Fountzilas, George
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Athens, CT, Greece
[2] Hlth Data Specialists Ltd, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14563
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [42] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    BMC CANCER, 2015, 15
  • [43] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    BMC Cancer, 15
  • [44] A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)
    Osumi, H.
    Ishizuka, N.
    Takashima, A.
    Kumekawa, Y.
    Nakano, D.
    Shiozawa, M.
    Denda, T.
    Sawada, R.
    Ouchi, K.
    Wakatsuki, T.
    Boku, N.
    Kato, K.
    Yamaguchi, K.
    Shinozaki, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S739 - S739
  • [45] Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
    Osumi, Hiroki
    Ishizuka, Naoki
    Takashima, Atsuo
    Kumekawa, Yosuke
    Nakano, Daisuke
    Shiozawa, Manabu
    Denda, Tadamichi
    Sawada, Ryoichi
    Ouchi, Kota
    Wakatsuki, Takeru
    Narikazu, Boku
    Kato, Ken
    Yamaguchi, Kensei
    Shinozaki, Eiji
    BMJ OPEN, 2022, 12 (09):
  • [46] A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
    Yee Chao
    Jan-Sing Hsieh
    Hsien-Tang Yeh
    Yu-Chieh Su
    Cheng-Chung Wu
    Jen-Shi Chen
    Cheng-Jeng Tai
    Li-Yuan Bai
    Kun-Huei Yeh
    Wu-Chou Su
    Chung-Pin Li
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 799 - 806
  • [47] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Muro, Kei
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Iwasaki, Kouji
    Soeda, Junpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Muro, K.
    Uetake, H.
    Tsuchihara, K.
    Shitara, K.
    Yamazaki, K.
    Ota, M.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Yamanaka, K.
    Mori, I.
    Soeda, J.
    Hihara, M.
    Yamanaka, T.
    Akagi, K.
    Ochiai, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
    Chao, Yee
    Hsieh, Jan-Sing
    Yeh, Hsien-Tang
    Su, Yu-Chieh
    Wu, Cheng-Chung
    Chen, Jen-Shi
    Tai, Cheng-Jeng
    Bai, Li-Yuan
    Yeh, Kun-Huei
    Su, Wu-Chou
    Li, Chung-Pin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 799 - 806
  • [50] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Watanabe, Jun
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Mori, Ikuo
    Yamanaka, Kazunori
    Hihara, Masamitsu
    Soeda, Junpei
    Yamanaka, Takeharu
    Akagi, Kiwamu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345